Skip to main content

Sangamo Therapeutics stock drops 23% on results of cutting-edge gene-editing trial

The trial marked the first instance of gene editing, or adding a new copy of a gene into the DNA of a patient’s cells, completed inside the body.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.